Market closed
Galectin Therapeutics/$GALT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Galectin Therapeutics
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Ticker
$GALT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
14
Website
GALT Metrics
BasicAdvanced
$132M
Market cap
-
P/E ratio
-$0.73
EPS
0.63
Beta
-
Dividend rate
Price and volume
Market cap
$132M
Beta
0.63
52-week high
$4.27
52-week low
$1.56
Average daily volume
390K
Financial strength
Current ratio
1.135
Quick ratio
1.071
Long term debt to equity
-101.681
Total debt to equity
-113.089
Interest coverage (TTM)
-8.49%
Management effectiveness
Return on assets (TTM)
-96.72%
Return on equity (TTM)
62.89%
Valuation
Price to book
-1.39
Price to tangible book (TTM)
-1.39
Price to free cash flow (TTM)
-3.89
Growth
Earnings per share change (TTM)
-4.54%
3-year earnings per share growth (CAGR)
10.46%
What the Analysts think about GALT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Galectin Therapeutics stock.
GALT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
GALT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
GALT News
AllArticlesVideos
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
GlobeNewsWire·4 weeks ago
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
GlobeNewsWire·1 month ago
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Galectin Therapeutics stock?
Galectin Therapeutics (GALT) has a market cap of $132M as of December 15, 2024.
What is the P/E ratio for Galectin Therapeutics stock?
The price to earnings (P/E) ratio for Galectin Therapeutics (GALT) stock is 0 as of December 15, 2024.
Does Galectin Therapeutics stock pay dividends?
No, Galectin Therapeutics (GALT) stock does not pay dividends to its shareholders as of December 15, 2024.
When is the next Galectin Therapeutics dividend payment date?
Galectin Therapeutics (GALT) stock does not pay dividends to its shareholders.
What is the beta indicator for Galectin Therapeutics?
Galectin Therapeutics (GALT) has a beta rating of 0.63. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.